Drug Profile
CAL 263
Alternative Names: CAL-263Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Calistoga Pharmaceuticals
- Class Anti-inflammatories
- Mechanism of Action Phosphatidylinositol 3 kinase delta inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Allergic rhinitis; Inflammation
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in Allergic-rhinitis in Austria (PO)
- 16 Jul 2016 No recent reports of development identified for phase-I development in Inflammation in USA (PO)
- 01 Apr 2011 Calistoga Pharmaceuticals has been acquired by Gilead Sciences